98%
921
2 minutes
20
The prevalence of metabolic syndrome in patients with schizophrenia has significantly increased and can be associated with severe complications such as chronic diseases and mortality. Despite numerous studies, a comprehensive estimate of the prevalence of metabolic syndrome in schizophrenia patients is lacking. Therefore, this study aimed to estimate the global prevalence of metabolic syndrome in schizophrenia patients through a systematic review and meta-analysis. This study was conducted as a systematic review and meta-analysis based on PRISMA guidelines without time restrictions until April 1, 2024. Relevant articles were identified through searches in databases including Scopus, Web of Science (WoS), PubMed, Science Direct, Embase, and Google Scholar, using key terms combined with AND & OR operators. After removing duplicates and conducting primary and secondary screening, 12 studies were included in the meta-analysis. Data were analysed using the random-effects model in Comprehensive Meta-Analysis Version 2 software. This analysis included 12 studies with 1,953 participants. The pooled prevalence of metabolic syndrome was 41.3% (95% CI: 28.8-55.1), with significant heterogeneity (I: 96.3%). The highest prevalence was reported in France (79.1%) and the lowest in China (18.03%). Over one-third of patients with schizophrenia are affected by metabolic syndrome. Hence, greater attention should be paid to the prevention and reduction of complications and mortality associated with metabolic syndrome in schizophrenia patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10935-024-00798-8 | DOI Listing |
Dev Dyn
September 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa, USA.
Background: Gene transcription is crucial for embryo and postnatal development and is regulated by the Mediator complex. Mediator is comprised of four submodules, including the kinase submodule (CKM). The CKM consists of MED13, MED12, CDK8, and CCNC.
View Article and Find Full Text PDFFront Mol Biosci
August 2025
Department of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.
Background: The clinical differentiation between obstetric antiphospholipid syndrome (OAPS) and undifferentiated connective tissue disease (UCTD) presents significant diagnostic challenges. This study employs metabolomics to investigate metabolic reprogramming patterns in OAPS and UCTD, aiming to identify potential biomarkers for early diagnosis.
Methods: Using LC-MS-based metabolomics, we analyzed serum profiles from 40 OAPS patients (B1), 30 OAPS + UCTD patients (B2), 27 UCTD patients (B3), and 30 healthy controls (A1).
Diabetes Metab Syndr Obes
September 2025
Department of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue City, Vietnam.
Background: Antipsychotics are associated with side effects like weight gain, obesity, and menstrual disorders in Women, which can reduce treatment compliance and increase cardiovascular, metabolic risks, dementia, and other chronic diseases, as well as increase mortality, and reduce the quality of life in patients. Data on these effects in Vietnam are limited. This study evaluated changes in body weight, BMI, menstrual cycle, and metabolic syndrome components among female schizophrenic inpatients treated with antipsychotics.
View Article and Find Full Text PDFCancer cachexia is a highly debilitating clinical syndrome of involuntary body mass loss featuring profound muscle wasting leading to high mortality. Notably, cardiac wasting is prominent in cancer patients and cancer survivors. Cachexia studies present significant challenges due to the absence of human models and mainly short-term animal studies.
View Article and Find Full Text PDFGenet Med Open
July 2025
Faculty of Biology Medicine and Health, University of Manchester, United Kingdom.
Purpose: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder. This study aimed to analyze the genotype distribution of FCS-causing genes in the United Kingdom.
Methods: Data were anonymously collated from 2 genetic testing laboratories providing national genetic diagnosis services for severe hypertriglyceridemia in the United Kingdom.